Piramal Pharma Share Price
Sector:
You have to be logged in to add this to Watchlist.
Login or Register
227.75 -4.70 (-2.02%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
226.2
Today’s High
236
52 Week Low
87.55
52 Week High
244.1
228.00 -4.38 (-1.88%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
226.05
Today’s High
235.99
52 Week Low
87.5
52 Week High
243.99
Key Metrics
- Market Cap (In Cr) 30662.17
- Beta -
- Div. Yield (%) 0.05
- P/B 3.89
- TTM P/E 746.2
- Peg Ratio 1.58
- Sector P/E 32.9
- D/E -
- Open Price 233.05
- Prev Close 232.45
Piramal Pharma Analysis
Price Analysis
-
1 Week3.69%
-
3 Months52.1%
-
6 Month64.23%
-
YTD67.36%
-
1 Year134.49%
Risk Meter
- 38% Low risk
- 38% Moderate risk
- 38% Balanced Risk
- 38% High risk
- 38% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 2
- 2
- 3
- 3
- Buy
- 3
- 3
- 2
- 1
- Hold
- 0
- 0
- 0
- 0
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 5
- 5
- 5
- 4
Piramal Pharma News
The US wants to cut its reliance on Chinese pharma. These stocks could benefit.
7 min read . 07 Oct 2024Piramal Pharma Solutions draws $80 mn expansion plan for US injectables facility
1 min read . 30 Sep 2024Stocks to Watch: IDFC First Bank, PNB, Dr Reddy's, REC, RIL, Welspun and more
2 min read . 30 Sep 2024Stocks to Watch: Vedanta, SpiceJet, SBI, Piramal Pharma, Shriram Finance & more
4 min read . 26 Sep 2024Piramal Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 8171.16
- Selling/ General/ Admin Expenses Total
- 2634.67
- Depreciation/ Amortization
- 740.57
- Other Operating Expenses Total
- -50.92
- Total Operating Expense
- 6683.37
- Operating Income
- 1487.79
- Net Income Before Taxes
- 179.29
- Net Income
- 17.82
- Diluted Normalized EPS
- 0.46
- Period
- 2024
- Total Assets
- 15311.81
- Total Liabilities
- 7400.44
- Total Equity
- 7911.37
- Tangible Book Valueper Share Common Eq
- 27.38
- Period
- 2024
- Cashfrom Operating Activities
- 1004.54
- Cashfrom Investing Activities
- -434.01
- Cashfrom Financing Activities
- -422.36
- Net Changein Cash
- 165.96
- Period
- 2023
- Total Revenue
- 7081.55
- Selling/ General/ Admin Expenses Total
- 2416.27
- Depreciation/ Amortization
- 676.69
- Other Operating Expenses Total
- -159.77
- Total Operating Expense
- 5937.62
- Operating Income
- 1143.93
- Net Income Before Taxes
- -120.15
- Net Income
- -186.46
- Diluted Normalized EPS
- -1.49
- Period
- 2023
- Total Assets
- 14522.56
- Total Liabilities
- 7749.06
- Total Equity
- 6773.5
- Tangible Book Valueper Share Common Eq
- 19.12
- Period
- 2023
- Cashfrom Operating Activities
- 483.89
- Cashfrom Investing Activities
- -1338.78
- Cashfrom Financing Activities
- 817.79
- Net Changein Cash
- -31.95
- Period
- 2022
- Total Revenue
- 6559.1
- Selling/ General/ Admin Expenses Total
- 1997.5
- Depreciation/ Amortization
- 586.18
- Other Operating Expenses Total
- -77
- Total Operating Expense
- 5264.9
- Operating Income
- 1294.2
- Net Income Before Taxes
- 484.98
- Net Income
- 375.96
- Diluted Normalized EPS
- 3.21
- Period
- 2022
- Total Assets
- 12797.04
- Total Liabilities
- 6100.44
- Total Equity
- 6696.6
- Tangible Book Valueper Share Common Eq
- 19.44
- Period
- 2022
- Cashfrom Operating Activities
- 843.16
- Cashfrom Investing Activities
- -1812.1
- Cashfrom Financing Activities
- 794.19
- Net Changein Cash
- -176.79
- Period
- 2021
- Total Revenue
- 2938.81
- Selling/ General/ Admin Expenses Total
- 456.69
- Depreciation/ Amortization
- 143.64
- Other Operating Expenses Total
- -52.4
- Total Operating Expense
- 1844.83
- Operating Income
- 1093.98
- Net Income Before Taxes
- 686.78
- Net Income
- 571.5
- Diluted Normalized EPS
- 4.7
- Period
- 2021
- Total Assets
- 5756.67
- Total Liabilities
- 1656.05
- Total Equity
- 4100.62
- Tangible Book Valueper Share Common Eq
- 30.78
- Period
- 2021
- Cashfrom Operating Activities
- 34.72
- Cashfrom Investing Activities
- -4382.89
- Cashfrom Financing Activities
- 4494.16
- Net Changein Cash
- 145.99
- Period
- 2024-06-30
- Total Revenue
- 1951.14
- Selling/ General/ Admin Expenses Total
- 579.69
- Depreciation/ Amortization
- 184.55
- Other Operating Expenses Total
- -19.54
- Total Operating Expense
- 1419.07
- Operating Income
- 532.07
- Net Income Before Taxes
- -45.08
- Net Income
- -88.64
- Diluted Normalized EPS
- -0.67
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2552.36
- Selling/ General/ Admin Expenses Total
- 526.05
- Depreciation/ Amortization
- 196.13
- Other Operating Expenses Total
- -26.38
- Total Operating Expense
- 1740.71
- Operating Income
- 811.65
- Net Income Before Taxes
- 227.48
- Net Income
- 101.27
- Diluted Normalized EPS
- 0.86
- Period
- 2024-03-31
- Total Assets
- 15311.81
- Total Liabilities
- 7400.44
- Total Equity
- 7911.37
- Tangible Book Valueper Share Common Eq
- 27.38
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1004.54
- Cashfrom Investing Activities
- -434.01
- Cashfrom Financing Activities
- -422.36
- Net Changein Cash
- 165.96
- Period
- 2023-12-31
- Total Revenue
- 1958.57
- Selling/ General/ Admin Expenses Total
- 523.78
- Depreciation/ Amortization
- 186.32
- Other Operating Expenses Total
- -61.51
- Total Operating Expense
- 1356.01
- Operating Income
- 602.56
- Net Income Before Taxes
- 19.36
- Net Income
- 10.11
- Diluted Normalized EPS
- 0.21
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 1911.38
- Selling/ General/ Admin Expenses Total
- 516.03
- Depreciation/ Amortization
- 184.51
- Other Operating Expenses Total
- -49.19
- Total Operating Expense
- 1289.08
- Operating Income
- 622.3
- Net Income Before Taxes
- 39.56
- Net Income
- 5.02
- Diluted Normalized EPS
- 0.04
- Period
- 2023-09-30
- Total Assets
- 14775.69
- Total Liabilities
- 7017.83
- Total Equity
- 7757.86
- Tangible Book Valueper Share Common Eq
- 25.88
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 508.25
- Cashfrom Investing Activities
- -107.18
- Cashfrom Financing Activities
- -386.52
- Net Changein Cash
- 19.99
- Period
- 2023-06-30
- Total Revenue
- 1748.85
- Selling/ General/ Admin Expenses Total
- 495.54
- Depreciation/ Amortization
- 173.61
- Other Operating Expenses Total
- -38.31
- Total Operating Expense
- 1257.57
- Operating Income
- 491.28
- Net Income Before Taxes
- -107.11
- Net Income
- -98.58
- Diluted Normalized EPS
- -0.83
- Period
- 2023-06-30
- Period
- 2023-06-30
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Piramal Pharma Technical
Moving Average
SMA
- 5 Day223.05
- 10 Day223.73
- 20 Day224.42
- 50 Day206.24
- 100 Day180.59
- 300 Day158.97
Piramal Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Tata Technologies
- 1082.7
- 5.15
- 0.48
- 1397.82
- 970.55
- 43921.73
- GO DIGIT GENERAL INSURANCE
- 365.5
- -3.3
- -0.89
- 407.55
- 277.8
- 33523.75
- Piramal Pharma
- 227.75
- -4.7
- -2.02
- 244.1
- 87.55
- 30130.14
- Global Health
- 1089.55
- -12.25
- -1.11
- 1513.75
- 707.6
- 29250.86
- Emcure Pharmaceuticals
- 1488.1
- 3.55
- 0.24
- 1577.5
- 1226.5
- 28139.73
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Tata Technologies
- 63.19
- 13.31
- 18.98
- 12.2
- GO DIGIT GENERAL INSURANCE
- 185.76
- 8.89
- -3.12
- -1.75
- Piramal Pharma
- 503.29
- 3.87
- -
- -
- Global Health
- 60.15
- 9.88
- -
- -
- Emcure Pharmaceuticals
- 56
- 9.49
- 19.6
- 7.81
Piramal Pharma Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 23-Oct-24
- Quarterly Results
- 26-Jul-24
- Quarterly Results
- 10-May-24
- Audited Results & Final Dividend
- 30-Jan-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results
- 03-Aug-23
- Quarterly Results
- 24-May-23
- Audited Results
- 08-Feb-23
- Quarterly Results & Rights issue
- 08-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 31-Jul-23
- 16-Jun-23
- AGM
- 22-Mar-23
- 20-Feb-23
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 10-May-24
- 12-Jul-24
- 12-Jul-24
- 0.11
- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 08-Feb-23
- 02-Aug-23
- 02-Aug-23
- 5:46
- 10
- 71
- Rights issue of equity shares of Rs. 10/- in the ratio of 5:46 @ premium of Rs. 71/-.